Cargando…
Can denosumab be a substitute, competitor, or complement to bisphosphonates?
Osteoblasts, originating from mesenchymal cells, make the receptor activator of the nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG) in order to control differentiation of activated osteoclasts, originating from hematopoietic stem cells. When the RANKL binds to the RANK of the pre-ost...
Autores principales: | Kim, Su Young, Ok, Hwoe Gyeong, Birkenmaier, Christof, Kim, Kyung Hoon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Pain Society
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392661/ https://www.ncbi.nlm.nih.gov/pubmed/28416991 http://dx.doi.org/10.3344/kjp.2017.30.2.86 |
Ejemplares similares
-
Can oliceridine (TRV130), an ideal novel µ receptor G protein pathway selective (µ-GPS) modulator, provide analgesia without opioid-related adverse reactions?
por: Ok, Hwoe Gyeong, et al.
Publicado: (2018) -
Future of bisphosphonates and denosumab for men with advanced prostate cancer
por: Iranikhah, Maryam, et al.
Publicado: (2014) -
Extraspinal Percutaneous Osteoplasty for the Treatment of Painful Bony Metastasis
por: Lee, Jae-Heon, et al.
Publicado: (2018) -
Review on the comparison of effectiveness between denosumab and bisphosphonates in post-menopausal osteoporosis
por: Benjamin, Biju, et al.
Publicado: (2016) -
The Role of Bisphosphonates Prior to Denosumab Treatment on Rebound Fractures: A Mini Review
por: Inojosa, Arthur Costa, et al.
Publicado: (2022)